Navitor Pharma

@NavitorPharma

Revealing the Therapeutic Power of mTORC1

Cambridge, MA
Vrijeme pridruživanja: ožujak 2014.

Tweetovi

Blokirali ste korisnika/cu @NavitorPharma

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @NavitorPharma

  1. 4. velj

    Congratulations to SAB member Michael Hall and Navitor Scientific Founder, , on for receiving the 2020 for the discovery of mTOR and its role in the control of cell metabolism and growth, laying the foundation for new cancer treatments.

    Poništi
  2. 22. sij

    Congratulations to , our scientific founder, on receiving Foundation Frontiers of Knowledge Award in Biomedicine for the discovery of mTOR.

    Poništi
  3. 13. sij

    Does location matter? CEO, Tom Hughes, moderated a panel yesterday ’s forum on emerging biotech clusters in the US.

    Poništi
  4. 8. sij

    Looking forward to a busy few days at and connecting with friends and colleagues. See you in San Francisco!

    Poništi
  5. 3. sij

    We want to thank retiring President and Chief Scientific Officer for his leadership and wisdom during his tenure at Navitor and express our gratitude for his continued guidance as a board member. CEO, Tom Hughes, will now be ’s President and CEO.

    Poništi
  6. 10. pro 2019.

    . CEO, Tom Hughes, gave a poster presentation today at showing how mTORC1 activation is a new mechanistic concept for antidepressants based on work with ketamine and other agents. . Read more here:

    Poništi
  7. 9. pro 2019.

    mTORC1 Activator NV-5138 shows rapid efficacy signals and favorable tolerability in treatment-resistant . Learn more in our poster presented at today.

    Poništi
  8. 5. pro 2019.

    Excited to be presenting data next week at from our Phase 1 program showing antidepressant effects and biomarker impact of NV-5138, a direct activator of mTORC1. Learn more here:

    Poništi
  9. 3. pro 2019.

    Always exciting to tell the Navitor story and how we are activating mTORC1 in the brain, particularly those regions associated with learning, memory formation and recall, and control of mood.

    Poništi
  10. 21. stu 2019.

    Tom Hughes, CEO during the Stifel 2019 Healthcare Conference discussing the company’s history, pipeline and novel approach to treat with clinical compound NV-5138, the first selective oral mTORC1 activator.

    Poništi
  11. 4. stu 2019.

    Excellent Neuroscience Spotlight Session . CMO Randy Owen presented data on Navitor’s NV-5138, a direct mTORC1 activator, for the treatment of depression.

    Poništi
  12. 23. lis 2019.

    Check out our poster presented today by Dr. Emilie Giaime . For more information on clinical compound NV-5138, the first selective oral mTORC1 activator for , our full poster can be found here:

    Poništi
  13. 22. lis 2019.

    Don't miss our poster session tomorrow where Dr. Emilie Giaime will answer questions on the clinical compound NV-5138, the first selective oral mTORC1 activator for . Abstract here:

    Poništi
  14. 12. ruj 2019.

    Proud to announce initial P1 results for NV-5138! Data show the rapid antidepressant effects and biomarker impact of our direct activator of mTORC1, and lay the groundwork for further development in . Read more here:

    Poništi
  15. 12. kol 2019.

    Thanks for hosting an informative CNS Therapeutics panel today. Our CEO Tom Hughes joined Dr. Robert Ostroff, Axsome Therapeutics and Intra-Cellular Therapies to discuss the ever-changing treatment landscape.

    Poništi
  16. 15. srp 2019.

    We are delighted to welcome Randy Owen, M.D. as our Chief Medical Officer! In this newly created position, Dr. Owen will lead clinical development of our pipeline of mTORC1-targeted therapeutics, including NV-5138 for treatment-resistant depression.

    Poništi
  17. 20. lip 2019.

    . paper details discovery of specific inhibitors of glucose transporter family exemplified by GLUT1-this comes from our efforts to discover novel selective modulators mTORC1 & expanded our unique understanding of this central metabolic pathway

    Poništi
  18. 5. lip 2019.

    Thank you @resTORbio and for an informative panel yesterday. Looking forward to continued innovations across the space as we collectively work to increase human healthspan.

    Poništi
  19. 4. lip 2019.

    Our CEO Tom Hughes is getting ready to discuss how we are translating our mTORC1 platform to bring forward new therapies to improve human health at the panel “Anti-Aging Therapies: Taking Action to Increase the Human Healthspan”

    Poništi
  20. 30. svi 2019.

    See you next week at ! Can’t wait to join and to discuss Anti-Aging Therapies: Taking Action to Increase the Human Healthspan on Tues. June 4th at 3:15pm.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·